Literature DB >> 18543130

Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Ozcan Met1, Jens Eriksen, Inge Marie Svane.   

Abstract

Previous studies have shown that mRNA-electroporated dendritic cells (DCs) are able to process and present tumor-associated antigens, leading to the activation of tumor-specific T cells in vitro and in vivo. However, the optimal maturation state of antigen loading and half-life of the mRNA-translated protein product and its immunogenic epitopes are significant parameters, which needs to be clarified in order to establish an effective electroporation protocol. In addition, despite extensive experimental investigations and their widespread application in research and clinical environments, little is known of the extent to which the immunological properties of DCs are influenced by electrical fields of critical strengths. We found that the mRNA transfection of DCs after maturation with short and low-voltage square-wave electrical pulses resulted in higher level of antigen expression and viability in addition to higher T-cell stimulatory ability compared to transfection of DCs prior to maturation. Mature mRNA-electroporated DCs showed long-lived expression of EGFP and were able to stimulate influenza matrix protein M1 (M1)-specific T cells up to 24 h after electroporation. However, when DCs were subjected to increasing electrical pulses the level of transgene expression was four-fold upregulated, equipping these DCs to be more potent in inducing M1-specific T cells. Also, the application of long electrical pulses induced further upregulation of HLA-DR, CD80, and CD86 expression in mature DCs, but did not promote phenotypic or functional maturation in immature DCs. These findings support the concept of mRNA transfection of DCs after maturation and also highlight the possibility to use long electrical pulses for further improvement of the immune responses by mRNA-transfected DCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18543130     DOI: 10.1007/s12033-008-9071-6

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  30 in total

1.  Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells.

Authors:  P A MacAry; M Lindsay; M A Scott; J I Craig; J P Luzio; P J Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

Authors:  D Boczkowski; S K Nair; J H Nam; H K Lyerly; E Gilboa
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.

Authors:  Laurence Chapatte; Maha Ayyoub; Sandra Morel; Anne-Lise Peitrequin; Nicole Lévy; Catherine Servis; Benoît J Van den Eynde; Danila Valmori; Frédéric Lévy
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

4.  Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.

Authors:  Niels Schaft; Jan Dörrie; Peter Thumann; Verena E Beck; Ina Müller; Erwin S Schultz; Eckhart Kämpgen; Detlef Dieckmann; Gerold Schuler
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

5.  mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT).

Authors:  Stein Saebøe-Larssen; Ellen Fossberg; Gustav Gaudernack
Journal:  J Immunol Methods       Date:  2002-01-01       Impact factor: 2.303

6.  Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.

Authors:  S K Nair; S Hull; D Coleman; E Gilboa; H K Lyerly; M A Morse
Journal:  Int J Cancer       Date:  1999-07-02       Impact factor: 7.396

7.  Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.

Authors:  Inge Marie Svane; Anders E Pedersen; Julia S Johansen; Hans E Johnsen; Dorte Nielsen; Claus Kamby; Svend Ottesen; Eva Balslev; Eva Gaarsdal; Kirsten Nikolajsen; Mogens H Claesson
Journal:  Cancer Immunol Immunother       Date:  2007-02-07       Impact factor: 6.968

8.  Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.

Authors:  Sandra Tuyaerts; Annelies Michiels; Jurgen Corthals; Aude Bonehill; Carlo Heirman; Catherine de Greef; Sofie M Noppe; Kris Thielemans
Journal:  Cancer Gene Ther       Date:  2003-09       Impact factor: 5.987

9.  A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

Authors:  L J Mu; G Gaudernack; S Saebøe-Larssen; H Hammerstad; A Tierens; G Kvalheim
Journal:  Scand J Immunol       Date:  2003-11       Impact factor: 3.487

10.  Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

Authors:  Matthew F Kalady; Mark W Onaitis; Karen M Padilla; Sirisha Emani; Douglas S Tyler; Scott K Pruitt
Journal:  J Surg Res       Date:  2002-06-01       Impact factor: 2.192

View more
  4 in total

Review 1.  New clinical advances in immunotherapy for the treatment of solid tumours.

Authors:  Valentina A Zavala; Alexis M Kalergis
Journal:  Immunology       Date:  2015-03-30       Impact factor: 7.397

2.  mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Authors:  Troels Holz Borch; Lotte Engell-Noerregaard; Trine Zeeberg Iversen; Eva Ellebaek; Özcan Met; Morten Hansen; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2016-07-08       Impact factor: 8.110

3.  In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes.

Authors:  Juan Sebastián Pappalardo; Cecilia A Langellotti; Sebastián Di Giacomo; Valeria Olivera; Valeria Quattrocchi; Patricia I Zamorano; William C Hartner; Tatyana S Levchenko; Vladimir P Torchilin
Journal:  Int J Nanomedicine       Date:  2014-02-13

4.  Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo.

Authors:  Soley Thordardottir; Nicolaas Schaap; Elja Louer; Michel G D Kester; J H Frederik Falkenburg; Joop Jansen; Timothy R D Radstake; Willemijn Hobo; Harry Dolstra
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.